Androgen therapy for anemia in elderly uremic patients

International Urology and Nephrology

Volumn 32, Issue 4, 2001, Pages 549-557

  Navarro, Juan F ^a   Mora, Carmen ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Androgens; Anemia; Elderly; Erythropoietin; Hemodialysis; Peritoneal dialysis

Indexed keywords

17ALPHA ALKYLATED ANDROGEN DERIVATIVE; ANABOLIC AGENT; ANDROGEN; ERYTHROCYTE ANTIBODY; ERYTHROPOIETIN; NANDROLONE DECANOATE; NANDROLONE DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT HORMONE; UNCLASSIFIED DRUG;

ACNE; AMENORRHEA; ANDROGEN THERAPY; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG COST; DRUG MECHANISM; DRUG POTENTIATION; ELDERLY CARE; ERYTHROCYTE TRANSFUSION; FLUSHING; HEMATOLOGICAL PARAMETERS; HEMATOPOIESIS; HEMODIALYSIS; HIRSUTISM; HOARSENESS; HUMAN; KIDNEY DISEASE; LIBIDO; LIVER DYSFUNCTION; NONHUMAN; PELIOSIS HEPATIS; PERITONEAL DIALYSIS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SPLEEN DISEASE; UREMIA; VIRILIZATION;

AGED; AGING; ANDROGENS; ANEMIA; DRUG THERAPY, COMBINATION; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 0035726908     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014491110361     Document Type: Review

References (99)

1. Testosterone replacement and the physiologic aspects of aging in men
2. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor I to growth hormone
3. Predictors of skeletal muscle mass in elderly men and women
4. Testosterone supplementation for hypogonadal impotence: Assessment of biochemical measures and therapeutic outcomes
5. Testosterone deficiency as a risk factor for hip fractures in men: A case-control study
6. The male sex accessory tissues: Structure, androgen action, and physiology
7. Androgens in men - Uses and abuses
8. Emerging issues in androgen replacement therapy
9. Secondary hypogonadism in older men: Its relation to impotence
10. Effect of age on bone density and bone turnover in men
11. An examination of research design effects on the association of testosterone and male ageing: Results of a meta-analysis
12. Bioavailability of albumin-bound testosterone
13. Transport of steroid hormones: Binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma
14. Biological actions of androgens
15. To what extent can spermatogenesis be maintained in the hypophysectomized adult rat testis with exogenously administered testosterone?
16. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men
17. Body composition and muscle strength in healthy men receiving testosterone enanthate for contraception
18. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
19. Replacement doses of testosterone increase fat-free mass, muscle size and strength in hypogonadal men
20. Anaemia in the elderly
21. The anemia of senescense
22. Effect of age on hematopoiesis in man
23. Iron status and anemia in the elderly: New findings and a review of previous studies
24. Hematologic data of healthy very old people
25. Age-related declines in hematopoietic reserve capacity
26. Anemia of end-stage renal disease (ESRD)
27. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin
28. Hormonal factors influencing erythropoiesis
29. Increased erythropoiesis induced by androgenic-hormone therapy
30. The erythrothaemic effects of androgens
31. The effect of sex hormones on the anemia induced by hemorrhage in the rat
32. Effects of hypophysectomy, castration, and testosterone propionate on hemopoiesis in the adult male rat
33. Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone
34. Erythropoietic response of dialyzed patients to testosterone
35. The hematologic effect of androgen in uremic patients. Study of packed cell volume and erythropoietin responses
36. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis
37. Nandrolone decanoate therapy for patients receiving hemodialysis: A controlled study
38. Testosterone for anaemia in maintenance dialysis
39. Oxymetholone in the treatment of anaemia in chronic renal failure
40. Cloning and expression of the human erythropoietin gene
41. Correction of anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial
42. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 hemodialysis-dependent patients
43. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease
44. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin
45. Erythropoietin and hypertension
46. Improvement of erythropoietin-induced hypertension changing the administration route
47. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease
48. Androgen versus erythropoietin for the treatment of anemia in hemodialysis patients: A prospective study
49. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis
50. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease
51. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients
52. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: A prospective study
53. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era
54. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis
55. Survey of the management of anemia in endstage renal disease (ESRD)
56. Androgens for the treatment of anemia in peritoneal dialysis patients
57. Mechanism of testosterone action in erytropoiesis
58. Erythropoietin excretion in man following androgens
59. Inhibition of erythropoiesic effects of hormones by erythropoietin antisera in mildly plethoric mice
60. The erythropoietic-stimulating effects of androgens
61. The effect of testosterone on erythropoietin levels in anemic patients
62. Erythropoietin and erythropoiesis in anemic man following androgens
63. Mechanisms of action of androgen treatment on the anemia of experimental chronic renal failure
64. Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures
65. Steroids and hematopoiesis I. The effect of steroids on in vitro erythroid colony growth: Structure/activity relationships
66. The role of androgens in the treatment of anemia of chronic renal failure
67. Effect of steroids on the cycling of haematopoietic stem cells
68. Androgen therapy in haemodialysis patients
69. Prospective controlled study of androgen therapy in the anemia of chronic renal disease: Effects of iron kinetics
70. Effects of androgenic steroids on erythropoiesis
71. Effects of androgen on transient endogenous spleen colonies and other hemopoietic stem cells in mice
72. Stimulatory effects of androgens on normal children's bone marrow in culture: Effects on BFU-E, CFU-E, and uroporphyrinogen I synthase activity
73. Enhanced erythroid burst formation in mice after testosterone treatment
74. Stimulation of hemoglobin synthesis in chick blastoderms by certain 5 β androstane and 5 β pregnane steroids
75. Studies on the control of hemoglobin synthesis: The in vitro stimulating effect of a 5 β-H steroid metabolite on heme formation in human bone marrow cells
76. Steroid control of porphyrin and heme biosynthesis: A new biological function on steroid hormone metabolites
77. Enhancement of heme and globin synthesis in cultured human marrow by certain 5β-H steroid metabolites
78. Androgen and erythropoiesis: Evidence for an androgen receptor in erythroblasts from human bone marrow cultures
79. The ontogeny of the androgen receptor in human foreskin
80. Augmentation of androgen-receptor binding in vitro: Studies in normals and patients with androgen insensitivity
81. Androgens and erythropoiesis
82. Hepatotoxic effects of the anabolic/androgenic steroids
83. Liver pathology associated with the use of anabolic-androgenic steroids
84. Peliosis in renal failure treated with androgens
85. Fulminant hepatic neoplasia after androgen therapy
86. Androgen-associated hepatoma in a hemodialysis patient
87. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels
88. Effects of testosterone supplementation in the aging male
89. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review
90. The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity
91. Lack of demonstrated effect of nandrolone on serum lipids
92. Nandrolone decanoate reduces lipoprotein(a) concentrations in hemodialysis patients
93. Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients
94. Lipids and lipoprotein (a) as risk factors for vascular disease in patients on renal replacement therapy
95. Effects of androgen therapy on prostatic markers in hemodialysis patients
96. Clinical practice guidelines for the treatment of anemia of chronic renal failure
97. Is there a role for adjuvant therapy in patients being treated with epoetin?